2 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 2 | Recruiting 2 |
Follow CCNE1 Amplification: new trials by email Literature Review of CCNE1 Amplification trials Research Report on CCNE1 Amplification
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of AVZO-021 in Patients With Advanced Solid Tumors AVZO-021, Palbociclib, Fulvestrant - Advanced Solid Tumor, HR+/HER2- Breast Cancer | Phase 1 / Phase 2 | Recruiting | Avenzo Therapeutics, Inc. | 430 | 2023-08-30 | 2026-09-28 |
| Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer INX-315, Fulvestrant, Abemaciclib - Breast Cancer, Breast Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | Incyclix Bio | 150 | 2023-03-28 | 2026-04-01 |
Breast Neoplasms (2) · Carcinoma, Ovarian Epithelial (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Adnexal Diseases (2) · Breast Diseases (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Gonadal Disorders (2) · Neoplasms (2) · Neoplasms by Site (2) · Ovarian Diseases (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2)
Fulvestrant (2) · abemaciclib (2) · Carboplatin (1) · Letrozole (1) · palbociclib (1) · ribociclib (1) · sacituzumab govitecan (1)
Avenzo Therapeutics, Inc. (1) · Incyclix Bio (1)
Australia (2) · United States (2)